The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Some information on the poster unveiled this afternoon, courtesy of someone on Reddit: https://twitter.com/AmandaCHorton/status/1777665021629149648?t=bFiTBaI7k345_1zBr9tLLQ&s=19
Synairgen have a track record of putting their poster presentations up on the company website-in the “investor” section. RNS or not. I would expect to see the poster lodged there relatively soon. My only proviso is that the lead agency in this case is not Synairgen themselves, but UKHSA. Whether that makes any difference, I couldn’t say although, imo, it shouldn’t.
Spacman, it’s a poster on a board in the exhibition hall or adjacent; not an oral presentation. So no open q&a but informal chat with delegates on a 1 to 1 basis at the board - assuming it is manned by one or more authors.
I agree hype is not the way to go. People who gambled on a “dead cert” with money they couldn’t afford to lose and then panicked and sold into eye watering losses deserve sympathy for their imprudence bordering on stupidity. But, for those who worked within their means and held their nerve when the world went sideways there is hope of a measure of recovery. And, for sure, there is going to be news soon, starting with something modest from Edinburgh on Tuesday. Not a case for another gold rush but progress nevertheless, imo.
I wonder what we might learn from the up-coming joint UKHSA/SNG poster presentation at the Microbiology. Society Annual Conference in Edinburgh on Tuesday. It covers work done at Porton Down with SNG001 tested in-vitro against a range of SARS-Cov19 variants. Replicating in-house sponsored testing in 2022, yes, but hopefully providing external validation of the “variant-agnostic” thesis. See A368 at: https://microbiologysociety.org/static/e2a41dbb-eafd-4056-89611c63c97bd6c7/AC24Poster-abstracts-booklet.pdf
Hope this is in Philip Monk’s in-tray. Indeed how could he not have been privy to the findings long since, given the close links between SNG, UNIVERSAL and Professor Chalmers? One has to wonder to what extent these findings will play a part in the stratification plan for at least one of the up-coming P2 studies. Looking forward to news on these very soon now.
Aimtrader. Your posts betray a profound ignorance of microbiology. A mycobacterium is not a virus and vice versa. Kind of key distinction on a site devoted to an antiviral agent, don’t you think?
Spaceman, I enjoy your informed and informative posts and share your frustration at the lack of progress made by the company as well as the languishing share price.
I do, however, take issue with your criticism of the company for not doing more to bolster the SP at this time. I wonder what you think the company could report in its support if, in reality, there is nothing to report in terms of progress pending intelligence from Universal and the start of the upcoming P2 trials. I am willing to be educated on this point.
The judgement of the CEO and Board is that now is the time to invest in this expensive senior appointment. This must have been based on more than a casual whim. The post, or one very similar in terms of role has been on the stocks for some time but the trigger has not been pulled until now. I do not believe the company is so stupid or negligent as to do so now in the absence of a compelling case.
I see today’s news more as a fundamental R&D re-set than a delay. If we are to believe that the new investigative strategy is an improvement of what went before, then the new timeframe, that we know is supported by the cash runway, is much easier to bear than a delay to the plans set out at the beginning of the year. Still painful, though!
Not too simplistic at all, TP. The problem with the Activ2 study in particular and even with our own P3 is that SNG was squeezed out of the competition for more severe cases. Why, I don’t know but it it a fact that the mix of patients randomised did not reflect that envisaged in the study protocols. The landscape is different now with Covid-19 trials few and far between and, we hope and trust, more rigorous selection criteria and monitoring BY SNG (!) than was the case certainly for the ACTIV study. Ergo, much higher probability of one or more of the shots on goal hitting its target.
Just so, TommyD. It would’ve been nice to have had more, but this “amuse-bouche“ represents confirmation that the study is progressing. The data on biomarkers will be fundamental to the success of the SNG P2 studies and the costs-of-care data will inform discussions with healthcare commissioners and potential partners in due course.
Two posters of relevance to SNG at the ERS today, one on UNIVERSAL and the other by Dr Monk summarising data from SNG001 trials. Both have been flagged here since the ERS programme was announced a coupl3 of months ago.